The present results confirm the widely recognized involvement of astrocytes at early clinical stages of prion diseases, as revealed by the altered mRNA expression of many astrocyte markers at 160 dpi, and increased GFAP immunoreactivity at 180 dpi. Here, GFAP is linked to prion disease.